Sermorelin
Endogenous GHRH Analog — The Original Compounded GH Secretagogue
Growth Hormone & Metabolism
Version 2025-04 · Last Reviewed April 1, 2025
About this review (v2025-04, last reviewed April 1, 2025): This review was compiled from published preclinical and clinical research, FDA regulatory documents, and compounding pharmacy guidance. No peptide vendor or manufacturer reviewed or approved this content. Read our full methodology
Educational content only. This page reflects published research and does not constitute medical advice. Peptides are not FDA-approved drugs (with limited exceptions noted). Consult a licensed healthcare provider before use. Dosing is intentionally omitted — it is determined by your provider based on individual labs and goals.
What it is
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH). It is the biologically active N-terminal segment of GHRH and stimulates the pituitary gland to release its own growth hormone in a physiological pulsatile pattern. Because it was previously FDA-approved, sermorelin has more human clinical data than most peptides in this category.
Regulatory status
Sermorelin was FDA-approved as Geref (sermorelin acetate for injection) for treatment of GH deficiency in children. It was withdrawn from the US market in 2008 for commercial reasons, not safety concerns. As a previously approved drug, it has an established human safety and pharmacology record. It can be compounded at licensed 503A pharmacies under physician prescription.
Mechanism of Action
Sermorelin binds the GHRH receptor on pituitary somatotroph cells, directly stimulating GH synthesis and release. The resulting GH release follows the body's natural pulsatile pattern (unlike direct HGH injection, which causes sustained non-pulsatile elevation). Sermorelin also appears to preserve or restore the normal GH axis feedback loop — as the pituitary's own stores of GH are used, it may maintain the gland's responsiveness rather than suppressing it (the opposite of what exogenous HGH does).
What Research Has Explored
These are areas of published research — not personal recommendations.
Growth hormone deficiency in adults
Multiple studies have demonstrated sermorelin's ability to raise IGF-1 levels and improve lean mass and fat distribution in adults with documented GH deficiency.
Context: Effect sizes are more modest than direct HGH therapy, reflecting the physiological cap on pituitary GH release versus pharmacological HGH dosing.
Age-related GH decline
In adults with age-related low GH, sermorelin increased IGF-1 into younger reference ranges and showed improvements in sleep quality and body composition in some studies.
Context: Whether treating 'low-normal' GH as opposed to frank deficiency is clinically meaningful remains debated among endocrinologists.
Pediatric growth hormone deficiency
Sermorelin (Geref) was FDA-approved for this indication. Extensive pediatric clinical data exists — though this application is now handled by direct HGH therapy in most cases.
Context: This is the best-evidenced application. Adult wellness use extrapolates from this foundational safety record.
Stability & Delivery Form — Why This Matters
Most peptides are fragile molecules destroyed by stomach acid and digestive enzymes. Delivery form determines whether the peptide survives to reach your bloodstream.
Capsule / Pill Warning
Sermorelin in capsule or pill form has no meaningful systemic bioavailability. Stomach acid and digestive enzymes destroy the peptide bonds before absorption. If a product is sold as a capsule claiming the systemic effects of the injectable form, it cannot deliver those effects. This is a red flag about the vendor's credibility.
Subcutaneous injection (lyophilized powder, reconstituted)
The only valid route. Identical stability requirements to other injectable peptides. Sermorelin has a short half-life (~10–20 minutes) — peak GH release occurs 15–45 minutes after injection.
Oral capsule
Sermorelin has no oral bioavailability. As a peptide, it is completely degraded in the GI tract before any systemic absorption can occur.
Reconstitution & Storage
Reconstitute with bacteriostatic water. Refrigerate at 2–8°C. Stability approximately 20–30 days refrigerated. Because sermorelin has a short half-life, timing of injection relative to desired GH pulse (typically before sleep) matters. Do not freeze reconstituted sermorelin.
Dosing is intentionally not listed here. It is determined by your provider based on individual labs, goals, and clinical context.
Frequently Asked Questions About Sermorelin
- What is Sermorelin?
- Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH). It is the biologically active N-terminal segment of GHRH and stimulates the pituitary gland to release its own growth hormone in a physiological pulsatile pattern. Because it was previously FDA-approved, sermorelin has more human clinical data than most peptides in this category.
- What is Sermorelin used for in research?
- Sermorelin has the most robust human clinical data of any compounded GH secretagogue due to its previous FDA-approval status, making it arguably the lowest-uncertainty option for physician-supervised GH axis support. Research areas include: Growth hormone deficiency in adults, Age-related GH decline, Pediatric growth hormone deficiency.
- Is Sermorelin FDA approved?
- Sermorelin was FDA-approved as Geref (sermorelin acetate for injection) for treatment of GH deficiency in children. It was withdrawn from the US market in 2008 for commercial reasons, not safety concerns. As a previously approved drug, it has an established human safety and pharmacology record. It can be compounded at licensed 503A pharmacies under physician prescription.
- How is Sermorelin administered?
- Subcutaneous injection only
- What are the safety risks of sourcing Sermorelin?
- Key risks when sourcing Sermorelin from grey-market or research suppliers include: Sermorelin's previously-approved status means legitimate compounding pathways exist — making grey market sourcing entirely unnecessary and substantially more dangerous than using a licensed pharmacy.; Research chemical vendors may substitute cheaper peptides (like GHRP-6 or modified GRF) for sermorelin. Without mass spectrometry verification, you cannot confirm what you are receiving.; Standard endotoxin contamination risks apply to any non-sterile injectable..
- Who should avoid or be cautious about Sermorelin?
- Sermorelin should be used with caution or avoided by: Active cancer or history of hormone-sensitive cancer — GH and IGF-1 are growth factors; consult oncologist.; Pituitary tumors or pituitary dysfunction — requires specialist evaluation before using any GHRH analog.; Type 2 diabetes with poor control — counter-insulin effect may worsen glycemia.; Pediatric use — use for GH deficiency should be under pediatric endocrinologist care, not via compounding without formal evaluation..
Stay informed — get updates when we add new medications
We add new medications and supplements regularly. No spam, ever.
No spam. Unsubscribe anytime.